Edesa Biotech(EDSA) - 2026 Q1 - Quarterly Results

Financial Performance - For the first quarter ended December 31, 2025, Edesa reported a net loss of $2.2 million, or $0.28 per common share, compared to a net loss of $1.6 million, or $0.48 per common share for the same period in 2024[6]. - Total operating expenses increased by $0.4 million to $2.3 million for the three months ended December 31, 2025, compared to $1.9 million for the same period in the previous year[5]. - General and administrative expenses increased by $0.3 million to $1.2 million for the three months ended December 31, 2025, primarily due to an increase in noncash share-based compensation[8]. - The company reported a decrease in total other income by $0.2 million to $0.1 million for the three months ended December 31, 2025, primarily due to reduced reimbursement funding from the Canadian government's Strategic Response Fund[5]. Research and Development - Research and development expenses rose by $0.1 million to $1.1 million for the three months ended December 31, 2025, primarily due to increased manufacturing-related activities[8]. - Edesa is exploring accelerated commercialization pathways for its monoclonal antibody paridiprubart following positive Phase 3 study results[4]. - Edesa plans to present its Phase 3 respiratory and subgroup data at upcoming scientific and medical conferences[3]. - The company plans to begin recruitment for its Phase 2 study in moderate-to-severe nonsegmental vitiligo by midyear 2026, subject to regulatory approvals[3]. Financial Position - Edesa had cash and cash equivalents of $12.1 million and working capital of $12.0 million as of December 31, 2025[7]. - Total assets increased to $14.7 million as of December 31, 2025, compared to $13.5 million as of September 30, 2025[15].